Lv0
0 积分 2025-07-16 加入
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers
12小时前
待确认
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
12小时前
已完结
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
12小时前
已完结
Plasmin-resistant PSD-95 inhibitors resolve effect-modifying drug-drug interactions between alteplase and nerinetide in acute stroke
6天前
已完结
Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study
6天前
已完结
PROTAC Cell Permeability and Oral Bioavailability: A Journey Into Uncharted Territory
1个月前
已完结
Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response
1个月前
已完结
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
2个月前
已完结
Translational Population‐Pharmacodynamic Modeling of a Novel Long‐Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia
2个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
2个月前
已完结
皖公网安备34019202002308
